Biotricity Inc. (BTCY) stock
BTCYOTCSurgical & Medical Instruments & ApparatusFiscal year ends March 31
$0.05+0.00 (+8.70%)
Close on Oct 19, 2026Market cap $1.15MP/E –Yield –
Biotricity r&d expenses
Research and development expenses are spending on new products and technology.
Biotricity's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.74M, up 17.3% year over year. For fiscal 2026 it was $2.76M, up 28.2% from the year before. The highest annual figure on record is $3.23M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $2.76M | +28.2% |
| FY2025 | Mar 31, 2025 | $2.16M | -16.2% |
| FY2024 | Mar 31, 2024 | $2.57M | -20.4% |
| FY2023 | Mar 31, 2023 | $3.23M | +17.7% |
| FY2022 | Mar 31, 2022 | $2.74M | +33.3% |
| FY2021 | Mar 31, 2021 | $2.06M | +51.0% |
| FY2020 | Mar 31, 2020 | $1.36M | +4.1% |
| FY2019 | Mar 31, 2019 | $1.31M | -25.7% |
| FY2018 | Mar 31, 2018 | $1.76M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $673.44K | -3.3% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $841.67K | +47.0% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $623.57K | +13.1% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $602.80K | +16.4% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $696.16K | +35.5% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $572.57K | -19.2% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $551.22K | +21.7% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $517.98K | -25.8% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $513.90K | -27.9% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $708.28K | +0.7% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $452.96K | -48.3% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $697.62K | +10.8% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $712.98K | -20.8% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $703.33K | +12.4% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $876.46K | +48.8% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $629.45K | +14.1% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $900.50K | +32.2% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $625.64K | +55.5% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $589.00K | +39.0% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $551.50K | +14.0% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $681.41K | +52.2% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $402.34K | +84.1% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $423.88K | +98.5% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $483.57K | -45.6% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $447.64K | -31.8% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $218.53K | -42.2% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $213.50K | -48.4% |
| Q1 FY2019CQ2 2018 | Dec 31, 2018 | $889.20K | +182.2% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $655.90K | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $377.92K | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $413.62K | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $315.11K | – |
See a number that looks wrong?